Clinical Trials List
2020-03-10 - 2025-07-31
Phase III
Not yet recruiting2
Recruiting3
Terminated1
ICD-10C50.011
Malignant neoplasm of nipple and areola, right female breast
ICD-10C50.012
Malignant neoplasm of nipple and areola, left female breast
ICD-10C50.019
Malignant neoplasm of nipple and areola, unspecified female breast
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9174.0
Malignant neoplasm of female breast, nipple and areola
-
-
Trial Applicant
NOVARTIS (TAIWAN) CO., LTD.
-
Sponsor
-
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/09/24
Investigators and Locations
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 沈士哲 未分科
- Wen-Ling Kuo 未分科
- Chi-Chang Yu 未分科
- 周旭桓 未分科
- Chia-Hui Chu 未分科
- Yung-Chang Lin 未分科
- Wen-Chi Shen 未分科
- Mengting Peng 未分科
- Chan-Keng Yang 未分科
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Co-Principal Investigator
- HWEI-CHUNG WANG Division of General Surgery
- Chen-Teng Wu Division of General Surgery
- Chih-Jung Chen Division of General Surgery
- Yao-Chung Wu Division of General Surgery
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Yu-Li Su Division of Hematology & Oncology
- 陳彥豪 Division of Hematology & Oncology
- 吳佳哲 Division of Hematology & Oncology
- 賴香蘭 未分科
- Shau-Hsuan Li Division of Hematology & Oncology
- 陳彥仰 Division of Hematology & Oncology
- Tai-Jan Chiu Division of Hematology & Oncology
- 李易濰 Division of Radiology
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Co-Principal Investigator
- Chia-Hui Chu Division of General Surgery
- 沈士哲 Division of General Surgery
- Wen-Chi Shen Division of Hematology & Oncology
- 周旭桓 Division of General Surgery
- Yung-Chang Lin Division of Hematology & Oncology
- Wen-Ling Kuo Division of General Surgery
- Mengting Peng Division of Hematology & Oncology
- Chi-Chang Yu Division of General Surgery
- Chan-Keng Yang Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- WEI-LI MA Division of Hematology & Oncology
- 林季宏 Division of Hematology & Oncology
- 張端瑩 Division of Hematology & Oncology
- Wei-Wu Chen Division of Hematology & Oncology
- 陳怡君 未分科
- MING-YANG WANG Division of General Surgery
- 羅喬 Division of General Surgery
- 陳怡君 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Study Contacts
- -
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
Exclusion Criteria
The Estimated Number of Participants
-
Taiwan
15 participants
-
Global
566 participants
